Ann: Shareholder Update, page-16

I am going to try to get the AGM next week, but if I don't make it, can someone take some eggs for me and egg the directors, please? After all, Easter is just around the corner. If I sell my shares now there should be enough for a carton of eggs and I will make it up to you.
Maybe, HC people can post questions they would like to ask directors too?
Here are some of mine:

1. Referring to the Investor Update that was released to the market in November 2016:

• when the Company stated that VF had "Proven potency and safety" what was the proof that they relied up?
• on what basis did the Company believe its lead program (VF-001 in venous leg ulcers) was a "de-risked lead program"?
• on what basis did the Company maintain that VF healed 3 times faster than clinical or community care?
• on what basis did the Company believe VF was a "derisked product with demonstrated efficacy"?
• when the Company made these statements did the Company believe VF had proven potency and safety and it was a de-risked product with demonstrated efficacy?
• Was it reasonable for investors to rely on these statements?
• Did the Company indicate in this Investor Update that there was a risk that VF would perform no better than standard care? If so, where?